The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses

Table of Contents

Executive Summary

• Industry overview
• Novartis (Sandoz)
• Bioton
• Teva
• LG Life Sciences
• Wockhardt
• Biocon
• Intas (Intas Biopharma)
• Emcure (Gennova)
• Hospira
• Ranbaxy

Chapter 1 Introduction

• Scope of the report
• Methodology

Chapter 2 Industry overview

• Summary
• Introduction
• The emerging biosimilar landscape
• Industry characteristics
  • Different market dynamics from standard generics
  • High R&D spend requires greater clinical investment
  • Intellectual property issues
• Regulations of biosimilars
  • Regulated markets
  • Semi-regulated markets
• Market Dynamics
• Global biosimilars market: size and growth
• Global positioning of the top 10 biosimilar companies
• Positioning of the top 10 biosimilar companies across off-patent biologic
• categories
• Product pipeline of the top 10 biosimilar companies
• Growth drivers and inhibitors
• Key trends in the industry
• Big pharmaceutical companies eyeing biosimilars
• Role of biosimilars in controlling healthcare expenditure
• Biosimilars of mAbs represent sizeable market opportunity
• Payors' acceptance of biosimilars as a means to reduce expenditure is
• expected to drive uptake
• Leading generics players with established market presence are spearheading
• biosimilar development
• Emergence of Indian biosimilar players to aid in market expansion
• Outlook

Chapter 3 Novartis (Sandoz)

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
  • Focus on expanding biosimilar product portfolio
• Acquisitions and divestments
• Partnerships and alliances
• SWOT analysis
• Strengths
  • Strongly positioned in the European biosimilars market
  • Strong R&D platform
• Weaknesses
  • Development set-backs for enoxaparin
• Opportunities
  • Developing cost-effective drugs
• Threats
  • FDA warnings on EPO products

Chapter 4 Bioton

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Expansion of biosimilars portfolio in drug categories other than insulin
• Acquisitions and divestments
• Partnerships and alliances
• SWOT analysis
• Strengths
  • Strong distribution network in the semi-regulated markets
  • Technical and regulatory experience
• Weaknesses
  • Lacks brand equity
• Opportunities
  • Entry in new markets
  • Initiatives in Asia
• Threats
  • Threat from analogue insulin

Chapter 5 Teva

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Growth strategies
  • Investing in R&D and manufacturing capabilities
• Acquisitions and divestments
• Partnership and alliances
• SWOT analysis
• Strengths
  • Global capabilities
• Weaknesses
  • Rising debt burden
• Opportunities
  • Growth through acquisitions
  • Joint-Venture with Lonza
  • Approval for marketing TevaGrastim in the EU
• Threats

Chapter 6 LG Life Sciences

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Shifting focus from independent R&D to strategic partnerships
• Acquisitions and divestments
• Partnerships and alliances
• SWOT analysis
• Strengths
  • Robust product portfolio
  • Research expertise
• Weaknesses
  • Relatively small size
• Opportunities
  • Launch of Declage
  • Targeting the antibody treatment segment
• Threats
  • Threat from large biotech companies

Chapter 7 Wockhardt

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Developing marketing and regulatory infrastructure capabilities
• Acquisitions and divestments
• Partnerships and alliances
• SWOT analysis
• Strengths
  • Robust manufacturing infrastructure
  • Domination of the Indian EPO market
  • Strong insulin portfolio in India
• Weaknesses
  • High debt burden
• Opportunities
  • Launch of Glaritus
• Threats
  • High competition for EPO in regulated markets

Chapter 8 Biocon

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Accessing competitive markets
• Acquisitions, divestments
• Partnership and alliances
• SWOT analysis
• Strengths
  • Strong position in the insulin market
• Weaknesses
  • Weaker geographic presence and scale
• Opportunities
  • Expanding biosimilar footprint in Europe
• Threats
  • Patent threat to biosimilars in India

Chapter 9 Intas (Intas Biopharma)

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Expansion into semi-regulated markets
• Restructuring sales network
• Acquisitions and divestments
• Partnership and alliances
• SWOT analysis
• Strengths
  • EU-GMP-certified manufacturing facilities
  • Expertise in filgrastim products development
• Weaknesses
  • Lack of direct distribution networks in regulated markets
• Opportunities
  • Expansion in regulated markets
  • Construction of mAb manufacturing facility
• Threats
  • Low demand for cancer biosimilars in India

Chapter 10 Emcure (Gennova)

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
  • Expansion in semi-regulated markets
• Acquisitions and divestments
• Partnership and alliances
• SWOT analysis
• Strengths
  • Strong R&D platform
• Weaknesses
  • Lack of marketing experience in the US
• Opportunities
  • Diversified product pipeline
  • Threats
  • Patent approval for biosimilars in India

Chapter 11 Hospira

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Expansion into regulated markets
• Acquisitions and divestments
• Partnerships and alliances
• SWOT analysis
• Strengths
  • Strong presence in Europe
• Weaknesses
  • Large debt burden
• Opportunities
  • Ability to leverage its strong distribution network in the US
• Threats
  • Overdependence on alliances

Chapter 12 Ranbaxy

• Summary
• Company overview
• Recent financial performance
• Marketed products
• Product pipeline
• Growth strategies
• Focus on alliances and in-licensing agreements
• Acquisitions and divestments
• Partnership and alliances
• SWOT analysis
• Strengths
  • Strong business model
• Weaknesses
  • High debt burden
• Opportunities
  • Penetrating market for osteoporosis
• Threats
  • Ban on Ranbaxy' s products

Chapter 1 Other major players

• Stada (Bioceuticals)
  • Company overview
  • Recent financial performance
  • Marketed products
  • Product pipeline
• Shreya Life Sciences
  • Company overview
  • Recent financial performance
  • Marketed products
• Dr Reddy' s
  • Company overview
  • Recent financial performance
  • Marketed products
  • Product pipeline
• Shantha Biotech
  • Company overview
  • Recent financial performance
  • Marketed products
  • Product pipeline
• MJ Biopharm
  • Company overview
  • Recent financial performance
  • Marketed products
• Shenzhen Neptunus Interlong
  • Company overview
  • Recent financial performance
  • Marketed products
• 3SBio
  • Company overview
  • Recent financial performance
  • Marketed products
  • Product pipeline
• Bharat Biotech
  • Company overview
  • Recent financial performance
  • Marketed products
• Pharmaclon
  • Company overview
  • Recent financial performance
  • Marketed products
• Panacea Biotech
  • Company overview
  • Recent financial performance
  • Marketed products

Chapter 2 Appendix

• Glossary
• The market for erythropoietins
• USA
• EU
• Japan
• Middle East
• Index